NLRP3 and acute respiratory distress syndrome: Moreover, several inhibitors of NLRP3 inflammasome have been demonstrated to exert beneficial effects for ALI in animal model tests which suggest that NLPR3 inflammasome might be a novel potential pharmaceutical target for the clinical treatment of ALI (17, 18).